| Name | Title | Contact Details |
|---|
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company`s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Aldagen is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stallergenes is a Norwell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioComm Network is a Laguna Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Optimum Outcomes is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.